» Articles » PMID: 30372452

Development of Reverse Genetics Systems and Investigation of Host Response Antagonism and Reassortment Potential for Cache Valley and Kairi Viruses, Two Emerging Orthobunyaviruses of the Americas

Abstract

Orthobunyaviruses such as Cache Valley virus (CVV) and Kairi virus (KRIV) are important animal pathogens. Periodic outbreaks of CVV have resulted in the significant loss of lambs on North American farms, whilst KRIV has mainly been detected in South and Central America with little overlap in geographical range. Vaccines or treatments for these viruses are unavailable. One approach to develop novel vaccine candidates is based on the use of reverse genetics to produce attenuated viruses that elicit immune responses but cannot revert to full virulence. The full genomes of both viruses were sequenced to obtain up to date genome sequence information. Following sequencing, minigenome systems and reverse genetics systems for both CVV and KRIV were developed. Both CVV and KRIV showed a wide in vitro cell host range, with BHK-21 cells a suitable host cell line for virus propagation and titration. To develop attenuated viruses, the open reading frames of the NSs proteins were disrupted. The recombinant viruses with no NSs protein expression induced the production of type I interferon (IFN), indicating that for both viruses NSs functions as an IFN antagonist and that such attenuated viruses could form the basis for attenuated viral vaccines. To assess the potential for reassortment between CVV and KRIV, which could be relevant during vaccination campaigns in areas of overlap, we attempted to produce M segment reassortants by reverse genetics. We were unable to obtain such viruses, suggesting that it is an unlikely event.

Citing Articles

The Temperature-Associated Effects of Rift Valley Fever Virus Infections in Mosquitoes and Climate-Driven Epidemics: A Review.

Azerigyik F, Cagle S, Wilson W, Mitzel D, Kading R Viruses. 2025; 17(2).

PMID: 40006972 PMC: 11860320. DOI: 10.3390/v17020217.


Innate Immune Response Against Batai Virus, Bunyamwera Virus, and Their Reassortants.

Zoller D, Saurich J, Metzger J, Jung K, Lepenies B, Becker S Viruses. 2025; 16(12.

PMID: 39772143 PMC: 11680289. DOI: 10.3390/v16121833.


Bunyavirales: Scientific Gaps and Prototype Pathogens for a Large and Diverse Group of Zoonotic Viruses.

Hartman A, Myler P J Infect Dis. 2023; 228(Suppl 6):S376-S389.

PMID: 37849397 PMC: 10582323. DOI: 10.1093/infdis/jiac338.


Comparison of Immunogenicity Between a Candidate Live Attenuated Vaccine and an Inactivated Vaccine for Cache Valley Virus.

Ayers V, Huang Y, Kohl A, Dunlop J, Hettenbach S, Park S Viral Immunol. 2023; 36(1):41-47.

PMID: 36622942 PMC: 9885547. DOI: 10.1089/vim.2022.0103.


Immunogenicity of a Candidate Live Attenuated Vaccine for Rift Valley Fever Virus with a Two-Segmented Genome.

Ayers V, Huang Y, Dunlop J, Kohl A, Brennan B, Higgs S Viral Immunol. 2022; 36(1):33-40.

PMID: 36399689 PMC: 9885543. DOI: 10.1089/vim.2022.0104.


References
1.
Johnson K, Zeddam J, Ball L . Characterization and construction of functional cDNA clones of Pariacoto virus, the first Alphanodavirus isolated outside Australasia. J Virol. 2000; 74(11):5123-32. PMC: 110865. DOI: 10.1128/jvi.74.11.5123-5132.2000. View

2.
Elliott R . Orthobunyaviruses: recent genetic and structural insights. Nat Rev Microbiol. 2014; 12(10):673-85. DOI: 10.1038/nrmicro3332. View

3.
Campbell G, Mataczynski J, Reisdorf E, Powell J, Martin D, Lambert A . Second human case of Cache Valley virus disease. Emerg Infect Dis. 2006; 12(5):854-6. PMC: 3374447. DOI: 10.3201/eid1205.051625. View

4.
Tilston-Lunel N, Acrani G, Randall R, Elliott R . Generation of Recombinant Oropouche Viruses Lacking the Nonstructural Protein NSm or NSs. J Virol. 2015; 90(5):2616-27. PMC: 4810690. DOI: 10.1128/JVI.02849-15. View

5.
Kraatz F, Wernike K, Hechinger S, Konig P, Granzow H, Reimann I . Deletion mutants of Schmallenberg virus are avirulent and protect from virus challenge. J Virol. 2014; 89(3):1825-37. PMC: 4300748. DOI: 10.1128/JVI.02729-14. View